We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Rapid HSV-2 Test Sets New Standard in STI Diagnostics

By LabMedica International staff writers
Posted on 28 Jul 2025

With an estimated 65 million Americans living with genital herpes and around 90% of those undiagnosed, there is an urgent need for faster, more efficient, accurate, and accessible testing methods. More...

Existing diagnostics, such as ELISA tests, commonly yield 17–22% equivocal results, resulting in misdiagnosis and delays in care. Specificity can be as low as 39.8% for certain index values, underscoring the inadequacy of current diagnostic tools. Such limitations often lead to uncertainty, distress, and postponed treatment, worsening patient outcomes. Now, a new rapid test for herpes simplex virus type 2 (HSV-2) addresses the limitations in STI diagnostics with its improved speed, accuracy, and accessibility.

Bio-Diagnostics Ltd.’s (Worcestershire, UK) HSV-2 BioCard test detects circulating antibodies to HSV-2 in the blood, indicating an active or past infection. Unlike HSV-1, which typically causes cold sores but can also lead to genital sores, HSV-2 is the primary cause of genital herpes, making accurate differentiation essential for treatment and limiting transmission. Bio-Diagnostics initially developed the BioCard HSV-2 testing technology as an accessible screening method to detect undiagnosed infections of genital HSV-2, but was later recommended by healthcare protection agencies to confirm around 20% of results that are left unclear by standard methods. The BioCard platform is also modular, supporting other diagnostic applications such as infectious diseases, autoimmune markers, toxins, and food safety.

The technology has been validated using blinded panels from UKHSA and MHRA NIBSC, demonstrating up to 100% sensitivity and 99.5% specificity for COVID-19 immunity tracking—further proving the reliability of the BioCard platform. It is the only technology to correctly identify every single UK NEQAS sample since its launch. Use of testing technologies by following the CDC guidelines resolves the compound effects of misdiagnosis, distress, and delayed care. The BioCard HSV-2 Rapid Test bridges this critical gap with point-of-care accuracy, simplicity, and global scalability. The BioCard HSV-2 test is typically administered in clinical settings or testing facilities by healthcare professionals, ensuring accurate diagnosis alongside access to supportive care. Bio-Diagnostics is now seeking new distribution partners and technology licensing collaborators to expand access across clinical, public health, and remote care settings.

Related Links:
Bio-Diagnostics Ltd


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Clinical Chemistry System
P780
New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.